Merus

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Company Growth (employees)

Type

Private

Utrecht, NL

Founded

2003

Size (employees)

69 (est)+2%

Website

merus.nl

Merus was founded in 2003 and is headquartered in Utrecht, NL

Key People/Management at Merus

Ton Logtenberg

CEO

John J. Crowley

Chief Financial Officer

John de Kruif

Chief Technology Officer

L. Andres Sirulnik

Chief Medical Officer

Lex Bakker

Chief Development Officer

Hui Liu

Chief Business Officer

Mark Throsby

Chief Scientific Office

Merus Office Locations

Merus has an office in Utrecht

Utrecht, NL (HQ)

62 Yalelaan

Utrecht, NL (HQ)

H.R. Kruytgebouw 8 Padualaan

Merus Financials and Metrics

Summary Metrics

Founding Date	2003
Total Funding	$149.3 m
Latest funding size	$79.1 m
Time since last funding	over 2 years
Investors	Novartis Venture Fund, Life Sciences Partners, Johnson & Johnson Innovation, Aglaia Oncology Fund, Bay City Capital, Tekla Capital Management, RA Capital Healthcare, Novo A/S, Pfizer Venture Investments, Sofinnova Ventures, Rock Springs Capital, Pfizer